Amneal Pharmaceuticals Files 8-K Report
Ticker: AMRX · Form: 8-K · Filed: Jul 21, 2025 · CIK: 1723128
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Amneal Pharma filed an 8-K on 7/21/25 - standard update, no major news yet.
AI Summary
On July 21, 2025, Amneal Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events or financial figures detailed in the provided text. The report confirms Amneal Pharmaceuticals, Inc. as the registrant, incorporated in Delaware, with its principal executive offices located in Bridgewater, NJ.
Why It Matters
This 8-K filing serves as a notification to the SEC and investors about significant corporate events or financial updates, though the specific details are not elaborated in this excerpt.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report without disclosure of any specific material events, risks, or financial changes.
Key Players & Entities
- Amneal Pharmaceuticals, Inc. (company) — Registrant
- July 21, 2025 (date) — Date of Report
- Bridgewater, NJ (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What is the primary purpose of this 8-K filing for Amneal Pharmaceuticals, Inc.?
The filing is a Current Report on Form 8-K, intended to report "Other Events" and "Financial Statements and Exhibits" as of July 21, 2025.
When was this 8-K report filed by Amneal Pharmaceuticals, Inc.?
The report was filed on July 21, 2025.
Where are the principal executive offices of Amneal Pharmaceuticals, Inc. located?
The principal executive offices are located at 400 Crossing Blvd, Bridgewater, NJ 08807.
In which state is Amneal Pharmaceuticals, Inc. incorporated?
Amneal Pharmaceuticals, Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number (EIN) for Amneal Pharmaceuticals, Inc.?
The IRS Employer Identification Number (EIN) for Amneal Pharmaceuticals, Inc. is 93-4225266.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 21, 2025 regarding Amneal Pharmaceuticals, Inc. (AMRX).